CompanyIMCRNasdaqOxfordshire, X0

Immunocore Ltd

Immunocore develops ImmTAX, a platform of TCR bispecific immunotherapies for cancer, autoimmune diseases, and infectious diseases.

SEC EDGAR ClinicalTrials.gov kimmtrakconnect.com

8-KSep 14Latest SEC filing, period to Sep 14

Sep 3Latest story

September 2026

UCSD registers Phase 2 study of low-dose dexamethasone to prevent Immunocore's tebentafusp CRS

Sep 3Trial updatedexamethasone Immunocore Ltd

August 2026

Immunocore posts Q2 KIMMTRAK sales growth as key melanoma trial nears enrollment target

Aug 6Quarterly updateImmunocore Ltd tebentafusp